1-(2,3,4-trimethoxy-benzyl)-piperidine | 108838-23-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(2,3,4-trimethoxy-benzyl)-piperidine
• 英文别名: 1-(2,3,4-Trimethoxy-benzyl)-piperidin；1-[(2,3,4-Trimethoxyphenyl)methyl]piperidine
• CAS: 108838-23-9
• 化学式: C₁₅H₂₃NO₃
• 分子量: 265.353
• InChiKey: RLBOGMKMOGHZTB-UHFFFAOYSA-N

物化性质

• 沸点：
  140-142 °C(Press: 1.5 Torr)
• 密度：
  1.070±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  30.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,3,4-三甲氧基苯甲醇 在 氯甲酸乙酯 、 potassium carbonate 作用下， 生成 1-(2,3,4-trimethoxy-benzyl)-piperidine
  参考文献：
  名称：

  Ring Enlargements. II. Attempted Ring Enlargement of Cyclohexanone with Ethyl N-Nitroso-N-(2,3,4-trimethoxybenzyl)-carbamate

  摘要：

  DOI：

  10.1021/ja01636a014

文献信息

• Hejno; Arnold, Chemicke Listy, 1953, vol. 47, p. 601,604
  作者：Hejno、Arnold

  DOI：——

  日期：——
• Methods of Diagnosing Diastolic Dysfunction
  申请人：Dudley Samuel

  公开号：US20120208762A1

  公开（公告）日：2012-08-16

  Diagnostic methods relating to a cardiac ventricular dysfunction are provided. In some embodiments, the diagnostic method is a method of diagnosing diastolic dysfunction in the absence of systolic dysfunction in a subject. The method comprises assaying a sample obtained from the subject for evidence of activation of renin-angiontensin system (RAS), evidence of oxidative stress, a level of adiponectin, or a combination thereof, wherein, when there is a lack of evidence of RAS activation, a lack of evidence of oxidative stress, a reduction in the level of adiponectin, or a combination thereof, as compared to a control subject, the subject is diagnosed with diastolic dysfunction in the absence of systolic dysfunction. A method of diagnosing a type of cardiac ventricular dysfunction, a method of determining a therapeutic regimen for a subject suffering from a cardiac ventricular dysfunction and methods of treating diastolic dysfunction in the absence of systolic dysfunction are also provided.
• METHODS OF TREATING DIASTOLIC DYSFUNCTION AND RELATED CONDITIONS
  申请人：Dudley Samuel

  公开号：US20120214818A1

  公开（公告）日：2012-08-23

  The invention provides a method of treating diastolic dysfunction, e.g., diastolic dysfunction with preserved ejection fraction, in a subject. The method comprises administering to the subject in an amount effective to treat the diastolic dysfunction a cardiac metabolic modifier, as described herein. In some embodiments, the diastolic dysfunction is characterized by (i) a lack of increased late I Na in cardiomyocytes, (ii) an increase in myofilament calcium sensitivity, or (iii) a combination thereof. In some embodiments, the subject does not suffer from a cardiac injury or a structural heart disease, as described herein. Further provided are a method of treating heart failure with preserved ejection fraction in a subject, a method of treating acute decompensated heart failure, a method of modulating myofilament calcium sensitivity in a subject, and a method of treating a condition associated with or caused by increased myofilament calcium sensitivity.
• MYOSIN BINDING PROTEIN-C FOR USE IN METHODS RELATING TO DIASTOLIC HEART FAILURE
  申请人：OF THE UNIVERSITY OF ILLINOIS THE BOARD OF TRUSTEES

  公开号：US20140011811A1

  公开（公告）日：2014-01-09

  The invention provides methods relating to the diagnosis and treatment of diastolic heart failure, kits for diagnosing diastolic heart failure or diastolic dysfunction, and related systems, computer readable storage media, and methods implemented by a processor in a computer.
• Ring Enlargements. II. Attempted Ring Enlargement of Cyclohexanone with Ethyl N-Nitroso-N-(2,3,4-trimethoxybenzyl)-carbamate
  作者：C. David Gutsche、Herbert E. Johnson

  DOI：10.1021/ja01636a014

  日期：1954.4